SARS-CoV-2 and COVID-19 Research

This study characterizes the molecular interfaces of the SARS-CoV-2 N protein's CTD and flanking IDRs, revealing their roles in oligomerization, RNA binding, and phase separation.

This paper identifies PA-001, a macrocyclic peptide that inhibits SARS-CoV-2 infection by targeting the S2 subunit's FPPR region, showing broad antiviral activity and efficacy in animal models and clinical trials.

The paper assesses the breadth and vulnerability of vaccine-induced SARS-CoV-2 neutralizing antibodies against emerging variants by analyzing their binding to conserved and variant-associated epitopes.

This study quantifies how exposure route, rather than dose, influences SARS-CoV-2 infection kinetics in non-human primates using a large meta-analysis of challenge experiments.

The paper surveys pets in households with human COVID-19 cases and finds 29% of pets tested positive for SARS-CoV-2, with cats more frequently infected than dogs.

The paper shows repeated SARS-CoV-2 vaccine boosters elicit variant-specific memory B cells and neutralizing antibodies, suggesting immune imprinting can be overcome with updated vaccines.

This study shows that deleting ORF6 from SARS-CoV-2 reduces virulence and pathogenicity in cats, with decreased immune suppression and reduced viral replication.

This study identifies MED13 and DDX60 as critical host factors for SARS-CoV-2 infection through a haploid genetic screen in mouse cells.

This study shows TMPRSS2 reduces antibody binding to SARS-CoV-2 spike by altering its structure and shedding, but not virion infectivity.

This study shows that re-infection with SARS-CoV-2 leads to broader and more potent antibodies against diverse sarbecovirus strains compared to antibodies from a prior infection.

The paper shows that mutations increasing ORF9b expression are common in SARS-CoV-2 variants and PCI sequences, suggesting ORF9b's role in viral evolution and immune evasion.

The paper examines how mutations in the HCoV-229E spike affect receptor binding and serum neutralization, revealing counterbalancing effects on these functions.

This study identifies an immunodominant S2 apex epitope in SARS-CoV-2 that elicits a public antibody clonotype, highlighting its role as a barrier to universal coronavirus vaccines.

The paper analyzes 449 SARS-CoV-2 genomic sequences from Algeria to trace viral evolution, identifying mutations, recombination events, and superspreading dynamics.

The paper assesses neutralizing antibody responses to multiple coronaviruses in Wuhan population samples before and after the pandemic, finding enhanced cross-neutralizing activity against sarbecoviruses.

The paper analyzes SARS-CoV-2-human protein-protein interactions to show Spike S may target cytoskeletal proteins via coiled-coil domains.

This paper develops a machine learning framework to predict human infection potential of coronaviruses using spike protein sequences, identifying motifs KIQ and LEP associated with human infection.

The paper identifies false positive inhibitors of NSP14 ExoN due to contaminating divalent cations, highlighting challenges in fragment-based drug development for this target.

This study identifies SARS-CoV-2 neutralizing antibodies and rapid viral RNA degradation in white-tailed deer milk, revealing distinct antiviral mechanisms compared to human milk.

This study evaluates the neutralizing antibody response induced by XEC-based monovalent vaccines against multiple SARS-CoV-2 variants, showing enhanced immunity against JN.1 subvariants compared to other variants.

This study identifies HGS-enlarged vesicular compartments as sites of coronavirus virion assembly at later infection stages using multiple imaging techniques.

This paper develops a stabilized MERS-CoV spike ferritin nanoparticle vaccine that elicits strong neutralizing antibodies in mice and non-human primates, providing protection against MERS-CoV infection.

This study compares intranasal and intramuscular vaccines, finding that the intranasal Ad4-S vaccine provides more durable and effective immune responses against SARS-CoV-2 in preclinical models.

This study examines how mutations in the spike protein of clade B lineage 5 MERS-CoV from 2015 to 2023 affect virus entry and replication, finding reduced entry and replication in 2019 variants but not in 2023 ones.

The paper identifies diverse spike haplotypes in persistent SARS-CoV-2 infections that show immune escape mechanisms similar to variants of concern.

This study compares DNA-LNP and mRNA-LNP vaccines against SARS-CoV-2 XBB.1.5, showing DNA-LNPs maintain durable immunity six months post-boost while mRNA-LNPs show waning protection.

This study identifies six ACE2 regions and peptides that can neutralize SARS-CoV-2, showing computational and experimental consistency across variants.

The paper identifies novel svRNA-triplex-forming oligonucleotides in SARS-CoV-2 and their evolutionary conservation and potential role in host adaptation and viral evolution.